Inquiry Basket
Loading ......
Feline immunodeficiency virus (FIV) is a complex lentivirus that causes an acquired immunodeficiency syndrome (AIDS)-like disease in domestic cats worldwide. First discovered in 1987 in a cattery in Petaluma, California, FIV has since emerged as a significant pathogen affecting feline health and as an invaluable small animal model for studying HIV pathogenesis and evaluating antiviral strategies. The virus belongs to the family Retroviridae, genus Lentivirus, and shares striking similarities with human immunodeficiency virus (HIV) in terms of genomic organisation, replication strategy, and disease progression. FIV infection progresses through acute, asymptomatic, and terminal AIDS-like phases, characterised by progressive depletion of CD4+ T lymphocytes, immune dysfunction, and increased susceptibility to opportunistic infections. With no curative treatment available and vaccine efficacy remaining variable, understanding the molecular basis of FIV pathogenesis is critical for developing effective control measures. This article synthesises current knowledge on FIV virology, pathogenesis, and key molecular targets that inform therapeutic and vaccine development.
Figure 1. Molecular structure and cell entry of feline immunodeficiency virus (fiv).
FIV is a member of the genus Lentivirus within the family Retroviridae, phylogenetically classified into five subtypes (A through E) based on envelope gene sequence diversity, with subtypes A and B being most prevalent in Europe and the Americas, respectively. The viral genome is a dimer of positive-sense, single-stranded RNA approximately 9,400 nucleotides in length, organised similarly to other lentiviruses but with distinctive features. The genome contains the canonical retroviral genes gag, pol, and env, flanked by long terminal repeats (LTRs) that contain regulatory elements for transcription. The gag gene encodes structural proteins: matrix (MA), capsid (CA), and nucleocapsid (NC). The pol gene encodes essential enzymes including protease (PR), reverse transcriptase (RT), dUTPase, and integrase (IN). Notably, FIV encodes a dUTPase—an enzyme absent in primate lentiviruses but present in non-primate lentiviruses—which reduces dUTP incorporation during reverse transcription and is important for replication in non-dividing cells such as macrophages. The env gene encodes the surface (SU, gp95) and transmembrane (TM, gp40) glycoproteins that mediate receptor binding and membrane fusion.
FIV replication follows the typical lentiviral lifecycle. Entry begins with binding of the surface glycoprotein (SU) to the primary cellular receptor CD134, a member of the tumour necrosis factor receptor superfamily that is expressed primarily on activated CD4+ T lymphocytes. This interaction induces conformational changes that expose a binding site for the chemokine coreceptor CXCR4, leading to membrane fusion and viral core entry. Following uncoating, the viral RNA is reverse transcribed by the viral RT into double-stranded DNA, a process facilitated by the dUTPase that minimises uracil misincorporation. The pre-integration complex, containing integrase and other viral proteins, is transported into the nucleus where integrase catalyses insertion of the viral DNA into the host genome. Viral gene expression is directed by the LTR promoter, with Rev facilitating nuclear export of unspliced genomic RNA and singly spliced env mRNA. Assembly occurs at the plasma membrane, with Gag and Gag-Pol polyproteins and genomic RNA coalescing into nascent virions that bud from the cell surface and undergo protease-mediated maturation.
FIV encodes and interacts with numerous host molecules that represent critical points for therapeutic intervention and vaccine design. Understanding these molecular targets provides fundamental insights into lentiviral pathogenesis and opportunities for translational development.
| Key Molecular Targets | Details |
| Viral Entry Receptors: CD134 and CXCR4 | The primary receptor for FIV is CD134 (also known as OX40), an activation marker specifically upregulated on activated CD4+ T lymphocytes. This selective expression pattern explains the preferential targeting and depletion of CD4+ T cells during FIV infection, mirroring HIV pathogenesis but without using CD4 as a receptor. |
| Viral Enzymes: Protease, Reverse Transcriptase, and Integrase | The essential enzymatic activities encoded by the FIV pol gene represent classical antiviral drug targets. The FIV protease processes Gag and Gag-Pol polyproteins during virion maturation and is inhibited by HIV protease inhibitors, enabling repurposing studies. Reverse transcriptase catalyses RNA-dependent DNA synthesis and is the target for nucleoside/nucleotide inhibitors such as zidovudine (AZT). |
| Regulatory Proteins: Rev and OrfA | The Rev protein mediates nuclear export of unspliced and singly spliced viral RNAs through interaction with the Rev response element (RRE) within the viral RNA. This post-transcriptional regulation is essential for viral replication. The OrfA protein, though not essential in immortalised T-cell lines, enhances replication in primary peripheral blood lymphocytes and may function analogously to HIV Tat, though its precise mechanism remains incompletely defined. |
FIV employs sophisticated strategies to evade host immunity. The selective upregulation of CD134 on activated CD4+ T cells ensures that the virus targets precisely the cells required for effective adaptive immunity. The Vif-mediated degradation of fA3 proteins prevents lethal hypermutation, while the Vif proteins of different subtypes exhibit varying anti-fA3 activities that correlate with viral pathogenicity. Additionally, FIV establishes latency in infected cells, enabling persistence despite host immune responses. The emergence of CRD2-independent variants during chronic infection reflects viral adaptation to declining CD134+ target cell populations and altered tissue compartmentalisation, demonstrating the dynamic co-evolution of virus and host.
The feline model offers unique advantages for evaluating antiviral strategies. HIV protease and reverse transcriptase inhibitors show efficacy against FIV, supporting the use of naturally infected cats as a translational model. The detailed molecular understanding of FIV entry—particularly the V3-CXCR4 interaction—provides opportunities for developing broad-spectrum entry inhibitors. Vaccination strategies targeting Rev and OrfA have been explored to induce early CTL responses, though protective efficacy remains to be optimised. The correlation between Vif function, APOBEC3 antagonism, and viral subtype pathogenicity suggests that therapeutic enhancement of intrinsic immunity could represent a novel approach.
Feline immunodeficiency virus remains a significant pathogen of domestic cats and an invaluable small animal model for human AIDS research. Recent advances have elucidated key molecular targets including the CD134 receptor, CXCR4 coreceptor, Vif-APOBEC3 interactions, and essential viral enzymes. Understanding these targets at the molecular level provides a foundation for developing novel antiviral therapies, optimising vaccine strategies, and illuminating fundamental principles of lentiviral pathogenesis. The continued study of FIV-host interactions promises to yield insights applicable to both feline medicine and human HIV research.
| Target | Cat. No. | Product Name | Host | |
| FIV | DAG-WT3377 | Native Feline Immunodeficiency Virus Antigen | N/A | Inquiry |
| DAG-WT715 | Native FIV Antigen (Petaluma) | CRFK cells | Inquiry | |
| FIV Core Antigen | DAG552 | Recombinant FIV Core Antigen | E. coli | Inquiry |
| FIV p24 | DAG-WT714 | Recombinant FIV p24 Antigen | E. coli | Inquiry |
Loading ......
